Neuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-Available

An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has made DAYBUE STIX, a dye- and preservative-free powder formulation of Rett syndrome drug trofinetide, broadly available across the U.S. after a limited early 2026 launch. The portable, mix-to-taste formulation targets adults and children from two years old, with early caregiver feedback showing high satisfaction and aligning with expert recommendations that position trofinetide as part of standard Rett syndrome care.

The expanded U.S. rollout of DAYBUE STIX deepens Neuren’s footprint in rare neurological diseases and may strengthen the commercial trajectory of its lead asset through greater flexibility and adherence in real-world use. Alongside this, Neuren continues to advance NNZ-2591 in Phase 3 trials for Phelan-McDermid syndrome and other rare pediatric indications, reinforcing its strategic focus on orphan neurodevelopmental disorders and potentially broadening its future revenue base.

The most recent analyst rating on (AU:NEU) stock is a Hold with a A$12.50 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals is an Australian biopharmaceutical company developing drug therapies for serious neurological disorders caused by genetic abnormalities or brain injury, where few or no treatments exist. Its programs focus on orally administered analogs of insulin-like growth factor 1 (IGF-1), including the approved Rett syndrome drug trofinetide and the pipeline candidate NNZ-2591 for multiple rare neurodevelopmental conditions.

Average Trading Volume: 554,810

Technical Sentiment Signal: Sell

Current Market Cap: A$1.52B

Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.